I think the honest answer to your question of when

I think the honest answer to your question of when they will care about the SP is if ALL of the following come true:

1) NGIO cannot list on a major exchange in the next few months and therefore will not be a source of funds in the short term

2) There is no cash infusion from any sort of CV-related activity in the next few months

3) Excellagen will definitely not be producing material cash flow in the next few months (probably true)

4) The NuGenHealth venture will not be producing cash flow in the next few months (hopefully there is something here, but the question is when and is it sufficient to support corporate operations?)

Have I missed any cash flow/revenue opportunities for the rest of this calendar year?

If ALL of these opportunities are failures, then they will care about the SP... for the simple reason that they will have to go back to the well for funding to sustain operations, and the well will be dry.

If any one of those opportunities keeps the ship afloat without having to raise money through other sources, the SP will not be on their radar for a while... IMHO, of course.